Clinical Efficacy of Capecitabine and Cyclophosphamide (XC) in Patients with Metastatic Breast Cancer
スポンサーリンク
概要
- 論文の詳細を見る
Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival. Here, a retrospective review was conducted of MBC patients administered XC at the Okayama University Hospital (OUH), to evaluate responses to XC, adverse events and time to progression (TTP). Twenty patients with MBC received XC between 2006 and 2009. With the exception of 2 elderly patients who were over the age of 70 at the initial examination, all of the patients had received prior treatment with an anthracycline and/or a taxane. No complete response (CR) cases were observed, but partial response (PR) was achieved in 6 patients (30%) and SD in 9 (45%), of whom 5 (20%) sustained SD status for >12 months. The median TTP was 6 months (range:3-27 mo.). Three patients developed Grade 3 adverse events (diarrhea, nausea and stomatitis), but no other patients developed adverse reactions causing interruption of the therapy. XC was safe even in previously treated and elderly MBC patients;moreover, it yielded remarkable clinical responses.
論文 | ランダム
- 405.行動科学的手法を用いた身体活動推進プログラムの効果に関する無作為割付比較対照試験(生活・健康)
- 25pXG-10 高強度レーザー生成プラズマデバイスによる高密度高エネルギー粒子の発生(プラズマ科学(ジャイロトロン・放電・レーザー),領域2(プラズマ基礎・プラズマ科学・核融合プラズマ・プラズマ宇宙物理))
- 355.健康づくり施設における身体活動量および全身持久性体力評価のための質問紙の検討(生活・健康)
- 25pXG-9 超高強度レーザー・プラズマ生成プラズマからの高速イオン発生研究5 : 発生機構の解明(プラズマ科学(ジャイロトロン・放電・レーザー),領域2(プラズマ基礎・プラズマ科学・核融合プラズマ・プラズマ宇宙物理))
- 7p-G-10 2次元超伝導ゆらぎ反磁性磁化率(Al)